<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811212</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00554</org_study_id>
    <secondary_id>NCI-2013-00554</secondary_id>
    <secondary_id>2012C0101</secondary_id>
    <secondary_id>RU241210I</secondary_id>
    <secondary_id>OSU 12154</secondary_id>
    <secondary_id>9312</secondary_id>
    <secondary_id>9312</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>UM1CA186705</secondary_id>
    <nct_id>NCT01811212</nct_id>
  </id_info>
  <brief_title>Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer</brief_title>
  <official_title>Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well cabozantinib-s-malate works in treating patients with&#xD;
      thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth&#xD;
      of thyroid cancer by blocking some of the enzymes needed for cell growth.&#xD;
      Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to&#xD;
      the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. The objective response rate, defined as the proportion of patients who have had a partial&#xD;
      response (PR) or complete response (CR) within the first 6 months after initiation of therapy&#xD;
      with cabozantinib (cabozantinib-s-malate).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess duration of objective response, progression-free survival and overall survival.&#xD;
&#xD;
      II. To assess tolerability and adverse events of cabozantinib as a 2nd line therapy in&#xD;
      patients with differentiated thyroid cancer (DTC).&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To assess effect of cabozantinib on serum tumor marker thyroglobulin and its correlation&#xD;
      with overall response rate.&#xD;
&#xD;
      II. To assess response of cabozantinib in bone metastasis (bone metastasis-specific&#xD;
      progression free survival) as evaluated by pre- and on-study functional imaging such as bone&#xD;
      scan, fludeoxyglucose F 18 (18F-FDG) positron emission tomography (PET) scan and/or 18F&#xD;
      sodium fluoride (NaF) PET scan.&#xD;
&#xD;
      III. To assess effect of cabozantinib on serum and urinary markers of bone turnover and its&#xD;
      correlation with response to bone metastasis.&#xD;
&#xD;
      IV. To assess predictors of response by performing tumor genotype studies (e.g. v-raf murine&#xD;
      sarcoma viral oncogene homolog B [BRAF], rat sarcoma [RAS],&#xD;
      phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [PIK3CA],&#xD;
      mitogen-activated protein kinase 1 [MAP2K1], v-akt murine thymoma viral oncogene homolog 1&#xD;
      [AKT1], mesenchymal-epithelial transition [MET], rearranged in transformation [RET]/papillary&#xD;
      thyroid carcinoma [PTC] rearrangement) in archived tumor tissue.&#xD;
&#xD;
      V. To assess predictors of response by assessing baseline expression levels of vascular&#xD;
      endothelial growth factor (VEGF), phosphorylated vascular endothelial growth factor receptor&#xD;
      (pVEGFR), phosphorylated mitogen-activated protein kinase 1 (pERK), phosphorylated AKT1&#xD;
      (pAKT) and/or total met proto-oncogene (MET) by immunohistochemistry in archived tumor&#xD;
      tissue.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cabozantinib-s-malate orally (PO) daily on days 1-28. Courses repeat every&#xD;
      28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks and then every 3&#xD;
      months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2013</start_date>
  <completion_date type="Actual">October 9, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover, as Measured by Serum and Urinary Markers of Bone Turnover</measure>
    <time_frame>Up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response as Assessed by the RECIST v1.1</measure>
    <time_frame>From date of documentation of response to the date of progression or death, assessed up to 1 year</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression Levels of Predictive Biomarkers of Response by Immunohistochemistry in Archived Tumor Tissue</measure>
    <time_frame>Baseline</time_frame>
    <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotype of Biomarkers Potentially Predictive of Response</measure>
    <time_frame>Baseline</time_frame>
    <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe (Grade 3+) Adverse Events, Graded According to the National Cancer Institute CTCAE v4.0</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Tolerability of the regimens will be assessed through assessing the number of patients who required dose modifications and/or dose delays. In addition, the proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from start of treatment to time of death, assessed up to 1 year</time_frame>
    <description>The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Tumor Marker Thyroglobulin Levels</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Side-by-side boxplots will be used to assess possible differences in this change between responders and non-responders, and scatterplots can assess the influence of baseline thyroglobulin levels on these measures of change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year</time_frame>
    <description>The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of Cabozantinib-s-malate in Bone Metastasis (Bone Metastasis-specific Progression Free Survival) as Evaluated by Functional Imaging</measure>
    <time_frame>Up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Poorly Differentiated Thyroid Gland Carcinoma</condition>
  <condition>Recurrent Thyroid Gland Carcinoma</condition>
  <condition>Stage I Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage I Thyroid Gland Papillary Carcinoma</condition>
  <condition>Stage II Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage II Thyroid Gland Papillary Carcinoma</condition>
  <condition>Stage III Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage III Thyroid Gland Papillary Carcinoma</condition>
  <condition>Stage IVA Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage IVA Thyroid Gland Papillary Carcinoma</condition>
  <condition>Stage IVB Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage IVB Thyroid Gland Papillary Carcinoma</condition>
  <condition>Stage IVC Thyroid Gland Follicular Carcinoma</condition>
  <condition>Stage IVC Thyroid Gland Papillary Carcinoma</condition>
  <condition>Tall Cell Variant Thyroid Gland Papillary Carcinoma</condition>
  <condition>Thyroid Gland Oncocytic Follicular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib S-malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed papillary thyroid cancer,&#xD;
             follicular thyroid cancer or hurthle cell thyroid cancer (cancer, follicular variant&#xD;
             of papillary thyroid cancers or any of the above mixed histology will be allowed;&#xD;
             these patients will be enrolled on Arm A of the trial); patients with the following&#xD;
             aggressive histologies will be enrolled on Arm B of the trial; tall cell, insular or&#xD;
             poorly differentiated thyroid cancer&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as &gt;= 2.0 cm with conventional&#xD;
             techniques or as &gt;= 1.0 cm (or &gt;= 1.5 cm in short axis for lymph node) with spiral&#xD;
             computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by&#xD;
             clinical exam&#xD;
&#xD;
          -  Patients must have radioactive iodine (RAI)-refractory/resistant disease as defined by&#xD;
             one or more of the following criteria:&#xD;
&#xD;
               -  One or more measurable lesions that do not demonstrate RAI uptake&#xD;
&#xD;
               -  One or more measurable lesions progressive by Response Evaluation Criteria in&#xD;
                  Solid Tumors (RECIST) 1.1 within 12 months of prior RAI therapy&#xD;
&#xD;
               -  One or more measurable lesion present after cumulative RAI dose of &gt;= 600 mCi&#xD;
&#xD;
          -  Patients must have &quot;progressed on&quot; up to 2 lines of prior vascular endothelial growth&#xD;
             factor receptor (VEGFR)-targeted therapy (including but not limited to sorafenib,&#xD;
             sunitinib, vandetanib, pazopanib, or lenvatinib) as defined by progressive disease per&#xD;
             RECIST while receiving VEGFR-targeted therapy; Note: patients who progressed on kinase&#xD;
             inhibitor that target VEGFR and MET will not be eligible&#xD;
&#xD;
          -  Prior external beam radiation, systemic cytotoxic chemotherapy or BRAF- or&#xD;
             non-VEGFR-targeted therapies will be allowed, provided that &gt;= 4 weeks has elapsed&#xD;
             since receiving prior treatment and they have recovered to =&lt; grade 1&#xD;
             treatment-related toxicities&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Thyroid stimulating hormone (TSH) &lt; lower limit of normal (LLN) (patients not able to&#xD;
             tolerate TSH suppression can be granted an exception)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (patients [Pts] with Gilbert's&#xD;
             syndrome are excluded from this requirement)&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and&#xD;
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 3.0 x&#xD;
             institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Serum albumin &gt;= 2.8 g/dL&#xD;
&#xD;
          -  Lipase &lt; 2.0 x ULN and no radiologic or clinical evidence of pancreatitis&#xD;
&#xD;
          -  Urine protein/creatinine ratio (UPCR) =&lt; 1&#xD;
&#xD;
          -  Serum phosphorus, calcium, magnesium and potassium &gt;= LLN&#xD;
&#xD;
          -  Prothrombin time (PT) &lt; 1.3 x ULN&#xD;
&#xD;
          -  International normalized ratio (INR) &lt; 1.3 x ULN&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) test &lt; 1.3 x ULN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at screening;&#xD;
             women of childbearing potential include women who have experienced menarche and who&#xD;
             have not undergone successful surgical sterilization (hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is&#xD;
             defined as amenorrhea &gt;= 12 consecutive months; Note: women who have been amenorrheic&#xD;
             for 12 or more months are still considered to be of childbearing potential if the&#xD;
             amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression&#xD;
             or any other reversible reason&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception;&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to study entry and for the duration of study participation; should a woman&#xD;
             become pregnant or suspect she is pregnant while she or her partner is participating&#xD;
             in this study, she should inform her treating physician immediately; men treated or&#xD;
             enrolled on this protocol must also agree to use adequate contraception prior to the&#xD;
             study, for the duration of study participation, and 4 months after completion of&#xD;
             cabozantinib administration; sexually active subjects (men and women) must agree to&#xD;
             use medically accepted barrier methods of contraception (e.g., male or female condom)&#xD;
             during the course of the study and for 4 months after the last dose of study drug(s),&#xD;
             even if oral contraceptives are also used; all subjects of reproductive potential must&#xD;
             agree to use both a barrier method and a second method of birth control during the&#xD;
             course of the study and for 4 months after the last dose of study drug(s)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with cabozantinib or any tyrosine kinase inhibitor that targets MET or&#xD;
             monoclonal antibody (mAb) targeting MET (such as onartuzumab [MetMAb])&#xD;
&#xD;
          -  The subject has received radionuclide treatment =&lt; 6 weeks of the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  The subject has received any other type of investigational agent =&lt; 28 days before the&#xD;
             first dose of study treatment&#xD;
&#xD;
          -  The subject has not recovered to baseline or Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) =&lt; grade 1 from toxicity due to all prior therapies except alopecia and&#xD;
             other non-clinically significant adverse events (AEs)&#xD;
&#xD;
          -  The subject has active brain metastases or epidural disease; subjects with brain&#xD;
             metastases previously treated with whole brain radiation or radiosurgery or subjects&#xD;
             with epidural disease previously treated with radiation or surgery who are&#xD;
             asymptomatic and do not require steroid treatment for at least 2 weeks before starting&#xD;
             study treatment are eligible; baseline brain imaging with contrast-enhanced CT or MRI&#xD;
             scans for subjects with known brain metastases is required to confirm eligibility;&#xD;
             eligible patients with brain metastases can be taking anti-convulsant medications but&#xD;
             only non-enzyme inducing anti-epileptic agents (NEIAED) will be allowed&#xD;
&#xD;
          -  The subject requires concomitant treatment, in therapeutic doses, with anticoagulants&#xD;
             such as warfarin or warfarin-related agents, heparin, thrombin or factor xabans (Xa)&#xD;
             inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=&lt; 81&#xD;
             mg/day), low-dose warfarin (=&lt; 1 mg/day), and prophylactic low molecular weight&#xD;
             heparin (LMWH) are permitted&#xD;
&#xD;
          -  The subject requires chronic concomitant treatment of strong cytochrome P450, family&#xD;
             3, subfamily A, polypeptide 4 (CYP3A4) inducers (e.g., dexamethasone, phenytoin,&#xD;
             carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St. John's Wort) or&#xD;
             strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, indinavir,&#xD;
             nefazodone, nelfinavir, ritonavir, voriconazole, and posaconazole); Note: because the&#xD;
             lists of these agents are constantly changing, it is important to regularly consult a&#xD;
             frequently-updated lists; medical reference texts such as the Physicians' Desk&#xD;
             Reference may also provide this information; as part of the enrollment/informed&#xD;
             consent procedures, the patient will be counseled on the risk of interactions with&#xD;
             other agents, and what to do if new medications need to be prescribed or if the&#xD;
             patient is considering a new over-the-counter medicine or herbal product&#xD;
&#xD;
          -  The subject has experienced any of the following:&#xD;
&#xD;
               -  Clinically-significant gastrointestinal bleeding =&lt; 6 months before the first&#xD;
                  dose of study treatment&#xD;
&#xD;
               -  Hemoptysis of &gt;= 0.5 teaspoon (2.5 mL) of red blood =&lt; 3 months before the first&#xD;
                  dose of study treatment&#xD;
&#xD;
               -  Any other signs indicative of pulmonary hemorrhage =&lt; 3 months before the first&#xD;
                  dose of study treatment&#xD;
&#xD;
          -  The subject has radiographic evidence of cavitating pulmonary lesion(s)&#xD;
&#xD;
          -  The subject has tumor that is invading or encasing any major blood vessels&#xD;
&#xD;
          -  The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus,&#xD;
             stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or&#xD;
             endobronchial tumor =&lt; 28 days before the first dose of cabozantinib&#xD;
&#xD;
          -  The subject has uncontrolled, significant intercurrent or recent illness including,&#xD;
             but not limited to, the following conditions:&#xD;
&#xD;
               -  Cardiovascular disorders including:&#xD;
&#xD;
                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) class III&#xD;
                       (moderate) or class IV (severe) at the time of screening&#xD;
&#xD;
                    -  Concurrent uncontrolled hypertension defined as sustained blood pressure&#xD;
                       (BP) &gt; 140 mmHg systolic, or &gt; 90 mmHg diastolic despite optimal&#xD;
                       antihypertensive treatment =&lt; 7 days of the first dose of study treatment&#xD;
&#xD;
                    -  Any history of congenital long QT syndrome&#xD;
&#xD;
                    -  Any of the following =&lt; 6 months before the first dose of study treatment:&#xD;
&#xD;
                         -  Unstable angina pectoris&#xD;
&#xD;
                         -  Clinically-significant cardiac arrhythmias&#xD;
&#xD;
                         -  Stroke (including transient ischemic attack [TIA], or other ischemic&#xD;
                            event)&#xD;
&#xD;
                         -  Myocardial infarction&#xD;
&#xD;
                         -  Thromboembolic event requiring therapeutic anticoagulation (Note:&#xD;
                            subjects with a venous filter [e.g. vena cava filter] are not eligible&#xD;
                            for this study)&#xD;
&#xD;
               -  Gastrointestinal disorders particularly those associated with a high risk of&#xD;
                  perforation or fistula formation including:&#xD;
&#xD;
                    -  Any of the following =&lt; 28 days before the first dose of study treatment&#xD;
&#xD;
                         -  Intra-abdominal tumor/metastases invading GI mucosa&#xD;
&#xD;
                         -  Active peptic ulcer disease as evidenced by esophagogastroduodenoscopy&#xD;
                            (EGD)&#xD;
&#xD;
                         -  Inflammatory bowel disease (including ulcerative colitis and Crohn's&#xD;
                            disease), diverticulitis, cholecystitis, symptomatic cholangitis or&#xD;
                            appendicitis&#xD;
&#xD;
                         -  Malabsorption syndrome&#xD;
&#xD;
                    -  Any of the following =&lt; 6 months before the first dose of study treatment:&#xD;
&#xD;
                         -  Abdominal fistula&#xD;
&#xD;
                         -  Gastrointestinal perforation&#xD;
&#xD;
                         -  Bowel obstruction or gastric outlet obstruction&#xD;
&#xD;
                         -  Intra-abdominal abscess; Note: complete resolution of an&#xD;
                            intra-abdominal abscess must be confirmed prior to initiating treatment&#xD;
                            with cabozantinib even if the abscess occurred more than 6 months&#xD;
                            before the first dose of study treatment&#xD;
&#xD;
               -  Other disorders associated with a high risk of fistula formation including&#xD;
                  percutaneous endoscopic gastrostomy (PEG) tube placement =&lt; 3 months before the&#xD;
                  first dose of study therapy&#xD;
&#xD;
               -  Other clinically significant disorders such as:&#xD;
&#xD;
                    -  Active infection requiring systemic treatment =&lt; 28 days before the first&#xD;
                       dose of study treatment&#xD;
&#xD;
                    -  Serious non-healing wound/ulcer/bone fracture =&lt; 28 days before the first&#xD;
                       dose of study treatment&#xD;
&#xD;
                    -  History of organ transplant&#xD;
&#xD;
                    -  History of major surgery as follows:&#xD;
&#xD;
                         -  Major surgery =&lt; 3 months of the first dose of cabozantinib if there&#xD;
                            were no wound healing complications or =&lt; 6 months of the first dose of&#xD;
                            cabozantinib if there were wound complications&#xD;
&#xD;
                         -  Minor surgery =&lt; 1 months of the first dose of cabozantinib if there&#xD;
                            were no wound healing complications or =&lt; 3 months of the first dose of&#xD;
                            cabozantinib if there were wound complications&#xD;
&#xD;
                         -  In addition, complete wound healing from prior surgery must be&#xD;
                            confirmed at least 28 days before the first dose of cabozantinib&#xD;
                            irrespective of the time from surgery&#xD;
&#xD;
          -  The subject is unable to swallow tablets&#xD;
&#xD;
          -  The subject has a corrected QT interval calculated by the Fridericia or Bazett's&#xD;
             formula (QTcF) &gt; 480 ms within 28 days before registration; Note: if initial QTcF or&#xD;
             QTcB is found to be &gt; 480 ms, two additional electrocardiograms (EKGs) separated by at&#xD;
             least 3 minutes should be performed; if the average of these three consecutive results&#xD;
             for QTcF or QTcB is =&lt; 480 ms, the subject meets eligibility in this regard&#xD;
&#xD;
          -  The subject is unable or unwilling to abide by the study protocol or cooperate fully&#xD;
             with the investigator or designee&#xD;
&#xD;
          -  The subject has had evidence within 2 years of the start of study treatment of another&#xD;
             malignancy which required systemic treatment&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to cabozantinib&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)&#xD;
             positive and currently receiving antiretroviral therapy; Note: patients known to be&#xD;
             HIV positive, but without clinical evidence of an immunocompromised state, are&#xD;
             eligible for this trial&#xD;
&#xD;
          -  The subject has received prior treatment with a small molecule kinase inhibitor or a&#xD;
             hormonal therapy (including investigation kinase inhibitors or hormones) within 14&#xD;
             days or five half-lives of the compound or active metabolites, whichever is longer,&#xD;
             before the first dose of the treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha Shah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.</citation>
    <PMID>28817373</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <results_first_submitted>December 11, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2018</results_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 2013 and January 2015 patients were enrolled by ITOG investigators at six centers in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="41" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover, as Measured by Serum and Urinary Markers of Bone Turnover</title>
        <time_frame>Up to 2 months</time_frame>
        <population>Data not collected to be analyzed at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover, as Measured by Serum and Urinary Markers of Bone Turnover</title>
          <population>Data not collected to be analyzed at this time</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response as Assessed by the RECIST v1.1</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>From date of documentation of response to the date of progression or death, assessed up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response as Assessed by the RECIST v1.1</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.3" upper_limit="NA">not evaluable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expression Levels of Predictive Biomarkers of Response by Immunohistochemistry in Archived Tumor Tissue</title>
        <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
        <time_frame>Baseline</time_frame>
        <population>Data has not been collected and analyzed at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Expression Levels of Predictive Biomarkers of Response by Immunohistochemistry in Archived Tumor Tissue</title>
          <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
          <population>Data has not been collected and analyzed at this time</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotype of Biomarkers Potentially Predictive of Response</title>
        <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
        <time_frame>Baseline</time_frame>
        <population>Data not collected to be analyzed at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Genotype of Biomarkers Potentially Predictive of Response</title>
          <description>These baseline levels will be quantitatively summarized and graphically explored, in particular in terms of how they relate to clinical outcomes of interest. Analyses exploring differences in these angiogenic and correlative markers in relation to clinical outcomes will be largely hypothesis-generating. With limited numbers of patients patterns of difference will primarily be looked for using graphical analyses; these can include plots of these marker levels in relation to clinical outcomes to identify potential patterns of interest.</description>
          <population>Data not collected to be analyzed at this time</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe (Grade 3+) Adverse Events, Graded According to the National Cancer Institute CTCAE v4.0</title>
        <description>The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Tolerability of the regimens will be assessed through assessing the number of patients who required dose modifications and/or dose delays. In addition, the proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial will be captured.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe (Grade 3+) Adverse Events, Graded According to the National Cancer Institute CTCAE v4.0</title>
          <description>The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Tolerability of the regimens will be assessed through assessing the number of patients who required dose modifications and/or dose delays. In addition, the proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial will be captured.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left ventricular systolic dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asymptomatic increased lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>osteonecrosis of the jaw</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decubitus ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>meningitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>perianal hidradenitis suppurativa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The Kaplan-Meier method will be used.</description>
        <time_frame>Time from start of treatment to time of death, assessed up to 1 year</time_frame>
        <population>the end of the range was not reached</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The Kaplan-Meier method will be used.</description>
          <population>the end of the range was not reached</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="18.3" upper_limit="NA">Not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Tumor Marker Thyroglobulin Levels</title>
        <description>Side-by-side boxplots will be used to assess possible differences in this change between responders and non-responders, and scatterplots can assess the influence of baseline thyroglobulin levels on these measures of change.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Data not collected to be analyzed at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Tumor Marker Thyroglobulin Levels</title>
          <description>Side-by-side boxplots will be used to assess possible differences in this change between responders and non-responders, and scatterplots can assess the influence of baseline thyroglobulin levels on these measures of change.</description>
          <population>Data not collected to be analyzed at this time</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>The Kaplan-Meier method will be used.</description>
        <time_frame>Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The Kaplan-Meier method will be used.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="10.9" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response of Cabozantinib-s-malate in Bone Metastasis (Bone Metastasis-specific Progression Free Survival) as Evaluated by Functional Imaging</title>
        <time_frame>Up to 2 months</time_frame>
        <population>Data not collected to be analyzed at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive Cabozantinib 60mg PO QD with dose escalation to 80mg QD or dose reduction to 40mg daily or 20mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Cabozantinib-s-malate in Bone Metastasis (Bone Metastasis-specific Progression Free Survival) as Evaluated by Functional Imaging</title>
          <population>Data not collected to be analyzed at this time</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was utilized for Adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cabozantinib S-malate: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis of the jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic increased lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Perianal hidradenitis suppurativa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Amenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other GI</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Liver transaminase elevation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lipase or amylase elevation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase elevation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other muscoskeletal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Peripherial neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Other dermatologic disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Proteninuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manisha Shah, MD</name_or_title>
      <organization>The Ohio State University Compreshive Cancer Center</organization>
      <phone>614-366-6994</phone>
      <email>manisha.shah@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

